As one of the immunotherapy strategies, ICI therapies, including anti-PD-1 and PD-L1 therapy, are considered to be a revolutionary milestone, disturbing coinhibitory signaling pathways, activating antitumor immune responses, and leading to the eradication of tumor cells [58]. The gene discussed is CD274; the disease is neoplasm.